FDA Approves First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis

The US Food and Drug Administration (FDA) has granted accelerated approval to Inovio Pharmaceuticals’ Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for adults with recurrent respiratory papillomatosis (RRP). The approval, announced on October 30, 2026, marks the first time a plasmid DNA-based immunotherapy has been approved in the United States.

RRP is a rare, long-term disease caused by human papillomavirus (HPV), mainly types 6 and 11. It leads to the development of small, wart-like growths called papillomas in the respiratory tract, particularly around the voice box and vocal cords. These growths can cause hoarseness, persistent coughing and changes in the voice. In more severe cases, they can spread through the airways and make breathing difficult.

There is currently no cure for RRP. Although surgery can remove the growths, the virus may remain in the affected tissues, meaning patients often need repeated procedures over several years. These repeated surgeries can also affect patients’ quality of life.

Voceryq is designed to address the underlying cause of the disease rather than only removing the growths. It is a plasmid DNA-based immunotherapy that aims to help the body’s immune system recognise and attack cells infected with HPV types 6 and 11.

The treatment delivers two plasmids, which are small pieces of DNA, into the body’s cells. One carries genetic instructions for specific HPV proteins, while the other contains interleukin-12 (IL-12), a molecule that helps strengthen the immune response.

Voceryq is given as an injection into the muscle using Inovio’s CELLECTRA 5PSP device. The device uses a process called electroporation, which applies brief electrical pulses to help deliver the treatment into cells.

The FDA’s decision was supported by results from an open-label, multicentre clinical trial involving 32 adults with RRP. Participants had undergone at least two surgeries to remove growths in the 12 months before starting treatment.

Among the 26 patients who had undergone at least three surgeries before treatment, seven (27%) did not require any further surgical intervention during the first year after receiving Voceryq. The findings suggest that the treatment may help reduce the need for repeated surgeries in some patients.

The most commonly reported side effects included injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness. The FDA also noted that the electrical pulses used during treatment may cause temporary effects such as muscle contractions, bleeding at the injection site and lightheadedness.

The approval was granted through the FDA’s accelerated approval pathway, which allows medicines for serious conditions to reach patients based on results that are considered reasonably likely to predict clinical benefit. Inovio will need to conduct additional clinical studies after approval to confirm the treatment’s clinical benefit.

Voceryq also received the FDA’s Breakthrough Therapy and Orphan Drug designations. The approval provides a new treatment option for adults with RRP, a condition that has historically required repeated surgical procedures and has had limited treatment choices.

You might also like